Apollomics Inc
Apollomics Inc is a biotechnology company focused on the development of targeted therapies for the treatment of cancer and other diseases.
Business. Apollomics Inc (APLM.O) is an investment holding company listed on the NASDAQ. The firm operates within the Financials sector, specifically classified under Investment Holding Companies. Detailed information regarding its operating segments and geographic presence is not available. The company is headquartered in the United States.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Apollomics Inc (APLM.O) is an investment holding company listed on the NASDAQ. The firm operates within the Financials sector, specifically classified under Investment Holding Companies. Detailed information regarding its operating segments and geographic presence is not available. The company is headquartered in the United States.
Apollomics Inc has a negative equity position of -$3.19 million and a cash and equivalents balance of $3.28 million, indicating a liquidity position that is below the typical thresholds for operational flexibility. The company's market capitalization of $36.02 million is supported by a market price of $16.4 per share, but its enterprise value to revenue ratio of 3.93 suggests a relatively high valuation given its current revenue of $8.5 million. The company's negative operating cash flow of -$10.37 million and free cash flow of -$10.48 million further highlight its liquidity constraints.
The company's profitability is challenged, with a net loss of $10.94 million and an operating loss of $11.2 million. Its return on equity of 3.43% is positive but modest, while its return on assets of -1.63% indicates that the company is not generating returns from its asset base. The company's debt to equity ratio of -0.2 suggests that it has more liabilities than equity, which is a concern for long-term financial stability.
Apollomics Inc's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue sources. The company's operations are likely concentrated in the biotechnology sector, which is subject to high research and development costs and regulatory risks.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The company's current financial performance, characterized by negative operating and net income, suggests that it is in a development phase and may not be generating significant revenue from its operations. The lack of capital expenditure indicates that the company is not investing in new assets, which could be a sign of financial constraints or a focus on research and development.
The risk assessment for Apollomics Inc indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative equity and high debt to equity ratio suggest that it may face financial challenges in the future. The company's dilution potential is low, but its financial position may require additional financing, which could lead to share dilution.
Recent events for Apollomics Inc include the latest financial data as of the most recent filing, which shows a continuation of financial losses and a reliance on cash reserves. The company's financial performance and liquidity position suggest that it is in a development phase and may require additional financing to support its operations.
- Apollomics Inc is a biotechnology company with a negative equity position and a cash and equivalents balance of $3.28 million.
- The company's profitability is challenged, with a net loss of $10.94 million and an operating loss of $11.2 million.
- The company's revenue is not segmented by product or geographic region, making it difficult to assess the concentration of its revenue sources.
- The company's growth trajectory is uncertain, with no specific revenue growth projections provided.
- The risk assessment for Apollomics Inc indicates low liquidity and dilution risks, but the company's financial position may require additional financing.
- "margin_outlook_rationale": "The company's margin outlook is negative due to its current net loss and operating loss.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 500exercise · 2026-06-15
- Director · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 500exercise · 2026-06-15
- Director · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 500exercise · 2026-06-15
- Director, Chief Operating Officer · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 5 000exercise · 2026-06-15
- Director · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 500exercise · 2026-06-15
- Director, Chief Financial Officer · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 10 000exercise · 2026-06-15
- Director, Chief Executive Officer · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 5 000exercise · 2026-06-15
- Director · Restricted Stock Units → CLASS A ORDINARY SHARESDisposed 500exercise · 2026-05-17
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Apollomics Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
- Director · CLASS A ORDINARY SHARESOther 500 · 2026-06-15
- Director, Chief Executive Officer · CLASS A ORDINARY SHARESOther 5 000 · 2026-06-15
- Director, Chief Financial Officer · CLASS A ORDINARY SHARESOther 10 000 · 2026-06-15
- Director, Chief Financial Officer · CLASS A ORDINARY SHARESOther 3 588 @ $13,85$50K · 2026-06-15
- Director · CLASS A ORDINARY SHARESOther 500 · 2026-06-15
- Director · CLASS A ORDINARY SHARESOther 500 · 2026-06-15
- Director · CLASS A ORDINARY SHARESOther 500 · 2026-06-15
- Director, Chief Operating Officer · CLASS A ORDINARY SHARESOther 5 000 · 2026-06-15
- Director · CLASS A ORDINARY SHARESOther 500 · 2026-05-17
- Chief Financial Officer · CLASS A ORDINARY SHARESOther 3 582 @ $15,85$57K · 2026-03-31